JFS Wealth Advisors’s Pacira BioSciences PCRX Stock Holding History

JFS Wealth Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$153	Buy	+6	New	+$142	﹤0.01%	2188
2024 Q3	–	Sell	-21	Closed	-$601	–	2006
2024 Q2	$601	Hold	21	–	–	﹤0.01%	1780
2024 Q1	$614	Hold	21	–	–	﹤0.01%	1749
2023 Q4	$709	Buy	21 +20	+2,000%	+$585	﹤0.01%	1727
2023 Q3	$31	Sell	1 -16	-94%	-$577	﹤0.01%	1947
2023 Q2	$682	Sell	17 -4	-19%	-$165	﹤0.01%	1703
2023 Q1	$858	Buy	21 +3	+17%	+$119	﹤0.01%	1623
2022 Q4	$695	Buy	18 +10	+125%	+$487	﹤0.01%	1680
2022 Q3	$0	Sell	8 -4	-33%	-$222	﹤0.01%	1874
2022 Q2	$1K	Sell	12 -3	-20%	-$197	﹤0.01%	1609
2022 Q1	$1K	Buy	15 +9	+150%	+$600	﹤0.01%	1701
2021 Q4	$0	Buy	+6	New	+$331	﹤0.01%	1836

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JFS Wealth Advisors's PCRX Position: Q2 2026 in Review

JFS Wealth Advisors opened a new position in Pacira BioSciences (PCRX) in Q2 2026: 6 shares worth $153. The stake represents ﹤0.01% of the portfolio and ranks #2188 among its holdings. This is a return to the name: JFS Wealth Advisors previously reported a position in PCRX as recently as Q2 2024.

JFS Wealth Advisors first reported a position in PCRX in Q4 2021 and has held it in 12 quarters since. The position peaked at $1K in Q2 2022. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

JFS Wealth Advisors held 6 shares of Pacira BioSciences worth $153 as of Q2 2026.
Pacira BioSciences was a new JFS Wealth Advisors position in Q2 2026.
Pacira BioSciences made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q2 2026, its #2188 holding.
JFS Wealth Advisors first reported a position in Pacira BioSciences in Q4 2021 and has held it in 12 quarters since.
JFS Wealth Advisors's Pacira BioSciences position peaked at $1K in Q2 2022.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on JFS Wealth Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.